A report by the Government Accountability Office says the FDA is giving fewer citations to drug companies for false and misleading advertising and is taking longer to do it. The report, set to be released today, says the volume and growth of direct-to-consumer drug ads has limited regulators' ability to curb ads that violate federal rules.

Full Story:

Related Summaries